◆ Market Data --:--
⛽ Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...

Devonian Health Group Inc.

GSD.V TSXV Healthcare Québec, Canada
Loading stock data...
Stock Performance
Price History
- Drag to select time range -
Market Data
Market Cap 38.0M
P/E Ratio -
52-Week High -
52-Week Low -
Avg Volume -
Beta -
Forward P/E -
Dividend Yield -
EV/Revenue -
Price/Book -
Business Overview

Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis. The company also develops Pantoprazole Magnesium for the treatment of gastric reflux; Cleo-35 for the treatment of hormonal acne in women; R-Spinasome anti-aging cream, serum, and regenerating creams; and anti-aging products, including day, night, and eye creams under the Purgenesis name. Devonian Health Group Inc. is headquartered in Québec, Canada.

Healthcare Biotechnology TSXV
Key Financial Metrics
23.6M
Revenue
-6.0M
Net Income
C$-2.46
EPS (Diluted)
-1.3M
Free Cash Flow
Profitability
Gross Margin 36.3%
Operating Margin -3.3%
Net Profit Margin -25.5%
EBITDA -5.1M
Returns & Efficiency
Return on Assets (ROA) -38.0%
Return on Equity (ROE) -65.8%
Dividend Yield -
Payout Ratio -
Financial Health
Total Assets 15.8M
Total Debt 125,804
Debt to Equity 0.01x
Current Ratio 1.32
Company Info
IndustryBiotechnology
HQQuébec, Canada
Employees8
Fiscal Year End1753920000
CurrencyCAD
Websitegroupedevonian.com
Peers
7.9B
P/E: --
2.5B
P/E: 12.0
2.5B
P/E: 23.7
2.2B
P/E: 53.2
1.4B
P/E: 24.1
1.2B
P/E: --
1.1B
P/E: --
631.8M
P/E: --
Insider Activity
Sentiment Neutral
Shares Bought 0
Shares Sold 0
Total Transactions 1
SEDAR+ Filings
View All Filings
No SEDAR+ filings available

Filings will appear here once they are loaded from SEDAR+

Interactive Charts
Full Chart View
Company Profile
General Information
Company NameDevonian Health Group Inc.
TickerGSD.V
ExchangeTSXV
SectorHealthcare
IndustryBiotechnology
HeadquartersQuébec, Canada
Employees8
Fiscal Year End1753920000
CurrencyCAD
Websitegroupedevonian.com
Financial Summary
Market Cap38.0M
Revenue23.6M
Net Income-6.0M
P/E RatioN/A
EPS (Diluted)C$-2.46
Net Margin-25.5%
ROE-65.8%
Dividend YieldN/A
Business Description
Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis associated to radiotherapy, as well as in phase 2a clinical trial for ulcerative colitis. The company also develops Pantoprazole Magnesium for the treatment of gastric reflux; Cleo-35 for the treatment of hormonal acne in women; R-Spinasome anti-aging cream, serum, and regenerating creams; and anti-aging products, including day, night, and eye creams under the Purgenesis name. Devonian Health Group Inc. is headquartered in Québec, Canada.
NEWS
Loading news...
TRENDING
Loading...